The factor of fibroblacts-21 growth in the blood of patients with non-alcocholic fatty disease of liver at the background of hypertonic disease
DOI:
https://doi.org/10.15587/2313-8416.2016.67683Keywords:
factor of fibroblasts-21 growth, non-alcoholic fatty disease of liver, hypertonic disease, overweight, obesityAbstract
Aim of research: the study of the level of risk factor of fibroblast-21 growth in the blood plasma of patients with non-alcoholic fatty disease of liver at the background of hypertonic disease with overweight and obesity of the 1 degree.
Materials and methods: There were examined 50 patients with NAFDL at the background of HD. Among examined were 37 men and 33 women. Patients were 30-60 years old, the mean age was (49,15±2,43) years. The most patients had the duration of anamnesis of both NAFDL and HD less than 10 years.
The clinical-laboratory indices of blood and urine and biochemical indices of blood and FGF21 were determined in all patients using immune-enzyme method. The body weight of patients was assessed with the help of body mass index (BMI) – 25–30 kg/m2 was assessed as the overweight, 30 – 35 kg/m2 – as obesity of the 1 degree.
Results of research: the level of FGF21 in the blood plasma of patients with NAFDL at the background of HD is increased in the group with overweight comparing with practically healthy persons in more than 2,5times, and in patients with obesity of the 1 degree – in 3,8 times (р˂0,05). At comparison of the received data was revealed that the levels of АсАТ exceeded the indices of the control group in 2 and 2,3 times, АlАТ in 2,5 and 3 times in the first and second groups respectively (р˂0,05). There were studied the correlations between the level of FGF21 and several studied indices. There were found the direct correlation between FGF21 and blood glucose (r=0,37, р˂0,001), АсАТ (r=0,49, р˂0,001), (r=0,61, р˂0,001), GC (r=0,39, р˂0,001) and TG (r=0,21, р˂0,02).
Conclusions: In patients with NAFDL at the background of HD are observed the higher levels of FGF21 in blood plasma. The increase of FGF21 was associated with the disturbance of carbohydrate and lipid metabolism, enzyme activity of the liver
References
Welsh, J. A., Karpen, S., Vos, M. B. (2013). Increasing Prevalence of Nonalcoholic Fatty Liver Disease Among United States Adolescents, 1988–1994 to 2007–2010. The Journal of Pediatrics, 162 (3), 496–500.e1. doi: 10.1016/j.jpeds.2012.08.043
Bekaert, M., Verhelst, X., Geerts, A., Lapauw, B., Calders, P. (2015). Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obesity Reviews, 17 (1), 68–80. doi: 10.1111/obr.12333
Bojarynova, M. A., Rotar', O. P., Konrady, A. O. (2014). Adypokynу y kardyometabolycheskyj syndrom. Arteryal'naja gypertenzyja, 20 (5), 422–432.
Reshetilov, Ju. I., Bogoslav, T. V., Kuznjecova, L. P. (2014). Osoblyvosti likuval'nogo harchuvannja hvoryh na arterial'nu gipertenziju. Gastroenterologija, 3, 84–88.
Chen, S.-J., Yen, C.-H., Huang, Y.-C., Lee, B.-J., Hsia, S., Lin, P.-T. (2012). Relationships between Inflammation, Adiponectin, and Oxidative Stress in Metabolic Syndrome. PLoS ONE, 7 (9), e45693. doi: 10.1371/journal.pone.0045693
Drapkyna, O. M., Popova, Y. R. (2013). Rol' ozhyrenyja v razvytyy arteryal'noj gypertenzyy y nealkogol'noj zhyrovoj bolezny pecheny. Ukrai'ns'kyj medychnyj chasopys, 2, 125–128.
Farrell, G. C., Wong, V. W.-S., Chitturi, S. (2013). NAFLD in Asia – as common and important as in the West. Nat Rev Gastroenterol Hepatol, 10 (5), 307–318. doi: 10.1038/nrgastro.2013.34
Musso, G., Cassader, M., Rosina, F., Gambino, R. (2012). Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia, 55 (4), 885–904. doi: 10.1007/s00125-011-2446-4
Fracanzani, A. L., Valenti, L., Bugianesi, E., Andreoletti, M., Colli, A., Vanni, E. et. al (2008). Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology, 48 (3), 792–798. doi: 10.1002/hep.22429
Iglesias, P., Selgas, R., Romero, S., Diez, J. J. (2012). MECHANISMS IN ENDOCRINOLOGY: Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. European Journal of Endocrinology, 167 (3), 301–309. doi: 10.1530/eje-12-0357
Semba, R. D., Sun, K., Egan, J. M., Crasto, C., Carlson, O. D., Ferrucci, L. (2012). Relationship of Serum Fibroblast Growth Factor 21 with Abnormal Glucose Metabolism and Insulin Resistance: The Baltimore Longitudinal Study of Aging. The Journal of Clinical Endocrinology & Metabolism, 97 (4), 1375–1382. doi: 10.1210/jc.2011-2823
Yang, S. J., Hong, H. C., Choi, H. Y., Yoo, H. J., Cho, G. J., Hwang, T. G. et. al (2011). Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clinical Endocrinology, 75 (4), 464–469. doi: 10.1111/j.1365-2265.2011.04078.x
Woo, Y. C., Xu, A., Wang, Y., Lam, K. S. L. (2013). Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives. Clinical Endocrinology, 78 (4), 489–496. doi: 10.1111/cen.12095
Wan, X., Lu, X., Xiao, Y., Lin, Y., Zhu, H., Ding, T. et. al (2014). ATF4- and CHOP-Dependent Induction of FGF21 through Endoplasmic Reticulum Stress. BioMed Research International, 2014, 1–9. doi: 10.1155/2014/807874
Yan, H., Xia, M., Chang, X., Xu, Q., Bian, H., Zeng, M. et. al (2011). Circulating Fibroblast Growth Factor 21 Levels Are Closely Associated with Hepatic Fat Content: A Cross-Sectional Study. PLoS ONE, 6 (9), e24895. doi: 10.1371/journal.pone.0024895
Yilmaz, Y., Eren, F., Yonal, O., Kurt, R., Aktas, B., Celikel, C. A. et. al (2010). Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. European Journal of Clinical Investigation, 40 (10), 887–892. doi: 10.1111/j.1365-2362.2010.02338.x
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M. et. al (2010). Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease. Gastroenterology, 139 (2), 456–463. doi: 10.1053/j.gastro.2010.04.054
Li, H., Fang, Q., Gao, F., Fan, J., Zhou, J., Wang, X. et. al (2010). Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Journal of Hepatology, 53 (5), 934–940. doi: 10.1016/j.jhep.2010.05.018
Stein, S., Stepan, H., Kratzsch, J., Verlohren, M., Verlohren, H.-J., Drynda, K. et. al (2010). Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism, 59 (1), 33–37. doi: 10.1016/j.metabol.2009.07.003
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Олег Якович Бабак, Катерина Аркадіївна Лапшина
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
